MEXILETINE AND SSRIS
Studies in patients and in vitro investigations have shown that fluoxetine and its metabolite, norfluoxetine, inhibit CYP2D6, the enzyme that metabolises mexiletine. Paroxetine would be expected to interact similarly. Fluvoxamine increases the AUC of mexiletine by 55% due to its effects on CYP1A2.
There appear to be no reported interactions with fluoxetine, but given the way it interacts with other CYP2D6 substrates it would seem prudent to be alert for increased and prolonged effects if it is given with mexiletine. Similar caution seems warranted with fluvoxamine.
There appear to be no reported interactions with fluoxetine, but given the way it interacts with other CYP2D6 substrates it would seem prudent to be alert for increased and prolonged effects if it is given with mexiletine. Similar caution seems warranted with fluvoxamine.